Dipeptidyl Peptidase 4 (Native Human)

<strong>Dipeptidyl Peptidase 4 (Native Human)</strong>_x000D_ <strong>Catalog number:</strong> B2016930_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 mU_x000D_ <strong>Molecular Weight or Concentration:</strong> 110 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -80°C_x000D_ <strong>Keywords:</strong> Dipeptidyl peptidase 4, Dipeptidyl peptidase IV, DPP IV, T-cell activation antigen CD26_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Suenaga A, Sawa N, Oba Y, Ikuma D, Sekine A, Hasegawa E, Mizuno H, Suwabe T, Ikeda S, Tsujimoto T, Kono K, Shintani-Domoto Y, Kinowaki K, Ohashi K, Miyazono M, Yamaguchi Y, Ubara Y. Dipeptidyl peptidase-4 inhibitor-related renal disease J Diabetes Complications. 2023 Oct;37(10):108590._x000D_ 2: Tschöp M, Nogueiras R, Ahrén B. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy Diabetologia. 2023 Oct;66(10):1796-1808._x000D_ 3: de Meester I, Vanhoof G, Lambeir AM, Scharpé S. Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3.4.14.5) J Immunol Methods. 1996 Jan 16;189(1):99-105._x000D_ 4: Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies Circ Res. 2014 May 23;114(11):1788-803._x000D_ 5: Lovshin JA, Zinman B. Blood pressure-lowering effects of incretin-based diabetes therapies Can J Diabetes. 2014 Oct;38(5):364-71._x000D_ 6: Hirano T, Mori Y. Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals J Diabetes Investig. 2016 Apr;7 Suppl 1(Suppl 1):80-6._x000D_ 7: Sfairopoulos D, Liatis S, Tigas S, Liberopoulos E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists Hormones (Athens). 2018 Sep;17(3):333-350._x000D_ 8: De Meester I, Vanhoof G, Hendriks D, Demuth HU, Yaron A, Scharpé S. Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes Clin Chim Acta. 1992 Sep 15;210(1-2):23-34._x000D_ 9: Angeli FS, Shannon RP. Incretin-based therapies: can we achieve glycemic control and cardioprotection? J Endocrinol. 2014 Mar 7;221(1):T17-30._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/31050435">10: Alavi SE, Cabot PJ, Moyle PM. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency Mol Pharm. 2019 Jun 3;16(6):2278-2295. </a>_x000D_ _x000D_ <strong>Products Related to Dipeptidyl Peptidase 4 (Native Human) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>